Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial

Circulation
Brian A BergmarkSAVOR-TIMI 53 Steering Committee and Investigators

Abstract

Metformin is first-line therapy for type 2 diabetes mellitus, although its effects on the cardiovascular system are unproved. In this post hoc analysis, patients in SAVOR-TIMI 53 (Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) with baseline biomarker samples (n=12 156) were classified as ever versus never taking metformin during the trial period. Associations between metformin exposure and outcomes were estimated with inverse probability of treatment weighting Cox modeling for the composite end point of cardiovascular death, myocardial infarction, or ischemic stroke, as well as cardiovascular death and all-cause mortality, with biomarkers included as covariates. Additional sensitivity analyses included propensity score matching and Cox multivariable models. Of the 12 156 patients with baseline biomarker samples, 8971 (74%) had metformin exposure, 1611 (13%) had prior heart failure, and 1332 (11%) had at least moderate chronic kidney disease (estimated glomerular filtration rate ≤45 mL·min-1·1.73 m-2). Metformin use was associated with no difference in risk for the composite end point (hazard ratio for inverse probability of treatment weighting, 0.92 [95% CI, 0.76-1.11]) but lower risk of all-...Continue Reading

References

May 21, 1999·Archives of Biochemistry and Biophysics·P D PrasadV Ganapathy
Oct 31, 2002·Equine Veterinary Journal. Supplement·C M DeatonR C Schroter
Jul 3, 2003·JAMA : the Journal of the American Medical Association·Frederick A MasoudiHarlan M Krumholz
Jan 31, 2006·Diabetes Care·Andrea SaloniaFrancesco Montorsi
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Feb 23, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·N DebackerV Van Casteren
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Sep 17, 2008·The American Journal of the Medical Sciences·Elvira O GosmanovaBarry M Wall
Jan 16, 2010·Kidney International·Steven Fishbane, Nobuyuki Miyawaki
Mar 9, 2010·Journal of Cardiac Failure·Digish D ShahTamara B Horwich
Mar 10, 2010·American Heart Journal·Adrian F HernandezGregg C Fonarow
May 18, 2010·International Journal of Cardiology·Francisco M Gomez-SotoFrancisco Gomez
Sep 22, 2010·The American Journal of Cardiology·Josie M M EvansChim C Lang
Oct 19, 2010·Circulation. Heart Failure·David AguilarAnita Deswal
Nov 26, 2010·Archives of Internal Medicine·Ronan RousselUNKNOWN Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators
Dec 25, 2010·The American Journal of Medicine·Yi-Ju ChenChun-Ying Wu
Jan 5, 2011·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A M HodgeG G Giles
Nov 15, 2011·Diabetes Research and Clinical Practice·David R WhitingJonathan Shaw
Apr 30, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Suetonia C PalmerGiovanni F M Strippoli
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Feb 27, 2020·Journal of the Chinese Medical Association : JCMA·Chern-En ChiangTze-Fan Chao
Sep 29, 2019·International Journal of Molecular Sciences·Andrea BaehrChristian Kupatt
Oct 13, 2020·Frontiers in Physiology·Mario SchubertKaomei Guan
Dec 3, 2020·Pharmaceuticals·Ehtasham AhmadMelanie J Davies
Dec 4, 2020·Current Opinion in Pharmacology·Graham RenaChim C Lang
Aug 21, 2020·IScience·Atul MalhotraJohn Y-J Shyy
Feb 4, 2021·Heart Failure Reviews·Maja NikolicVladimir Jakovljevic
Feb 16, 2021·Frontiers in Cell and Developmental Biology·Xudong ZhuZhenyu Ju
Jan 21, 2021·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jinghong LiAtul Malhotra
Dec 5, 2020·The Canadian Journal of Cardiology·Varinder Kaur RandhawaKim A Connelly
Mar 10, 2021·Current Atherosclerosis Reports·Muhammad Imtiaz Ahmad, Michael D Shapiro
Mar 24, 2021·Future Cardiology·Ez Alddin Rajjoub Al-MahdiJose L Zamorano
Apr 25, 2020·Journal of the American College of Cardiology·Tanya WilcoxJonathan D Newman
Mar 31, 2021·Cardiovascular Research·Qutuba G KarwiGary D Lopaschuk
May 20, 2021·Diabetes, Obesity & Metabolism·Jeremy OrloffJames Flory
Sep 2, 2021·JACC. Basic to Translational Science·Anja KarlstaedtBonnie Ky

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.